General discussion, page-11368

I recall that the lapsed oppies were related to a missed performances milestone as Covid caused a few strategic pivots that prevented the completion of these trials in original form or timeframe.
That said the resulting position now is far greater with more advanced Phase2 trial protocol and IP protection over treatment methods.

Did notice the word 'imminently' was used twice in Joel's AGM read out, as was TBI preclinical 'nearing conclusion'. With this kicker of a line..."Clinical trial activities are already planned to follow this study."

We are in a waiting time until next news but this doesn't show the huge progress that is being done concurrently including the Pre IND package for OSA.